Videos

Expert discusses updated cohort of patients with longer-term follow up treated in the phase 2 clinical trial of venetoclax added to cladribine plus low-dose araC alternating with azacytidine.

Expert discusses the updated data for a trial cohort after a median follow-up of 27 months.

Expert discusses the effect of baseline transfusion burden and luspatercept dose level on response to treatment in patients with LR-MDS from the MEDALIST study.

Expert discusses the results of a trial assessing immune reconstitution in adult patients who received Orca-T, consisting of hematopoietic stem/progenitor cells, regulatory T cells, and conventional T cells.

Expert discusses clinical outcomes of the phase 3 ZUMA-7 trial assessing axicabtagene ciloleucel versus standard-of-care in second-line large B-cell lymphoma by metabolic tumor volume.

Expert discusses the safety and efficacy of polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) as second-line treatment in a multicenter phase 2 study.

Expert discusses analysis of phase 3 MEDALIST trial data aimed to assess the probability of greater overall survival and progression-free survival benefit from luspatercept vs placebo.

Following a phase 2 analysis of OP-1250 with palbociclib, researchers recommend an OP-1250 dose level of 120 mg/day for future trials.

Guidelines for HER2-low expressed cancer could define who and how patient recieve drugs, said expert live from San Antonio Breast Cancer Symposium 2022.

OP-1250 and palbociclib showed “enhanced suppression of tumor growth” in preclinical mouse model studies, according to expert who presented his findings in a poster at the San Antonio Breast Cancer Symposium 2022.

Expert sits with Pharmacy Times to share the promising results of a study that evaluated the safety of a new antibody drug conjugate with radiation therapy.

Dawn L. Hershman, MD, MS, Columbia University Medical Center, New York, NY, presents her findings at the 2022 San Antonio Breast Cancer Symposium.

Researchers discovered the most common single gene mutation that causes treatment-resistance in first- line ER-positive or HER2-negative breast cancer treatment with a CDK4/6 inhibitor.

Breast cancer expert joined a panel to discuss aromatase inhibitors at the San Antonio Breast Cancer Symposium (SABCS) on December 6, 2022.

A new radiation therapy may reduce toxicity compared to standard therapy, paving the way for a safer and possibly, more effective, treatment of early-stage breast cancer.

Kalin Clifford, associate professor in the Geriatrics Division at Texas Tech University Health Sciences Center in the Jerry H. Hodge School of Pharmacy, discusses the potential benefits of herbal supplements for dementia care.

Dena Dillon, HIV clinical pharmacy specialist at the University of Iowa Health Care, discusses 2-drug regimens for individuals living with HIV.

Jawad Saleh, clinical manager of Pharmacy Services at the Hospital for Special Surgery, discusses how pharmacists can treat postoperative nausea and vomiting.

Tom Greenlee, retail pharmacy manager at the University of Missouri Health Care, and Kayla Hodges, 340B Analyst in Pharmacy Business at the University of Missouri Health Care, discuss how a successful career ladder can help retain pharmacy technicians.

O’Mally Monahan, vice president of Operations at McKesson RxO, discusses patient assistant programs and how they can reduce a delay in treatment.

Jacinda Abdul-Mutakabbir, assistant professor of Pharmacy Practice at Loma Linda University, discusses how pharmacists can improve vaccination rates and learn from the pandemic.

Michelle Condren, PharmD, AE-C, BCPPS, CDCES, FPPA, discussed pharmacists' roles in inpatient diabetes management.

Scott Soefje, director of Pharmacy Cancer Care and assistant professor of Pharmacy at Mayo Clinic, discusses the role of PD-1 inhibitors in treating non–small cell lung cancer.

Although it has received less attention as flu season begins, public health experts are continuing to urge vaccination against monkeypox.

Drs McHayleh and Vinokurov share final thoughts, highlighting the future of treatment for HR+/HER2- breast cancer.

Expert panelists discuss potential coming developments in the treatment landscape for breast cancer.

Parties and get-togethers often present challenges for patients with allergies, particularly with home-cooked food that may have unclear ingredients.

Drs Vinokurov and McHayleh discuss how the approach to breast cancer treatment may vary between academic and community health settings.

Drs Vinokurov and McHayleh discuss the impact of clinical trials on the treatment landscape of HR+/HER2- breast cancer.

Our Best Shot (OBS) is a new children’s book explaining why we should get an annual flu shot and it is not something to fear…and adults may even benefit, said the author.